复发性呼吸道乳头状瘤病药物治疗的研究进展

Research progress in the adjunct therapy of recurrent respiratory papillomatosis

复发性呼吸道乳头状瘤病(recurrent respiratory papillomatosis,RRP)是一种由人乳头瘤病毒(human papillomavirus,HPV)感染所致的呼吸道良性肿瘤,根据发病年龄可分为成人型复发性呼吸道乳头状瘤病(adult onset recurrent respiratory papillomatosis,AORRP)和幼年型复发性呼吸道乳头状瘤病(juvenile onset recurrent respiratory papillomatosis,JORRP)[1]。

Recurrent respiratory papillomatosis(RRP) is a benign tumor of the respiratory tract caused by human papillomavirus(HPV) infection. At present, there is no cure for this disease, and mainly depends on surgical resection to relieve symptoms but cannot prevent recurrence. Multiple surgeries will bring heavy mental and economic burdens to patients and their families. Therefore, researchers are constantly seeking new treatments to reduce the number of operations and prevent recurrence. Hence, research on adjuvant therapy drugs has also been widely carried out, including bevacizumab, cidofovir, HPV vaccine, and Chinese medicine as an adjuvant drug according some reports. This article reviews the adjuvant treatment of RRP in recent years.